261 related articles for article (PubMed ID: 22525883)
1. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.
Hébuterne X; Lémann M; Bouhnik Y; Dewit O; Dupas JL; Mross M; D'Haens G; Mitchev K; Ernault É; Vermeire S; Brixi-Benmansour H; Moreels TG; Mary JY; Marteau P; Colombel JF
Gut; 2013 Feb; 62(2):201-8. PubMed ID: 22525883
[TBL] [Abstract][Full Text] [Related]
2. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
5. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
Sandborn WJ; Abreu MT; D'Haens G; Colombel JF; Vermeire S; Mitchev K; Jamoul C; Fedorak RN; Spehlmann ME; Wolf DC; Lee S; Rutgeerts P
Clin Gastroenterol Hepatol; 2010 Aug; 8(8):688-695.e2. PubMed ID: 20451663
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.
Sandborn WJ; Lee SD; Randall C; Gutierrez A; Schwartz DA; Ambarkhane S; Kayhan C; Pierre-Louis B; Schreiber S; Lichtenstein GR
Aliment Pharmacol Ther; 2014 Oct; 40(8):903-16. PubMed ID: 25146586
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H
Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
Vavricka SR; Schoepfer AM; Bansky G; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Scharl M; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2011 Jul; 17(7):1530-9. PubMed ID: 21674709
[TBL] [Abstract][Full Text] [Related]
14. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.
Augustine JM; Lee JK; Armstrong EP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):599-609. PubMed ID: 25209304
[TBL] [Abstract][Full Text] [Related]
15. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab pegol for induction of remission in Crohn's disease.
Yamazaki H; So R; Matsuoka K; Kobayashi T; Shinzaki S; Matsuura M; Okabayashi S; Kataoka Y; Tsujimoto Y; Furukawa TA; Watanabe N
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012893. PubMed ID: 31476018
[TBL] [Abstract][Full Text] [Related]
17. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S
Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
[TBL] [Abstract][Full Text] [Related]
19. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S; Colombel JF; Bloomfield R; Nikolaus S; Schölmerich J; Panés J; Sandborn WJ;
Am J Gastroenterol; 2010 Jul; 105(7):1574-82. PubMed ID: 20234346
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
Rutgeerts P; Schreiber S; Feagan B; Keininger DL; O'Neil L; Fedorak RN;
Int J Colorectal Dis; 2008 Mar; 23(3):289-96. PubMed ID: 18071721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
